Clinical Trials ProgressThe company continues to enroll the Phase 3 CoMpass trial for bel-sar in early-stage choroidal melanoma and has registered over 240 patients in a pre-screening tool, up from 220 patients in mid-May.
Competitive PositioningRecent IP developments, including a new formulation patent with potential exclusivity to 2046, further strengthen Aura’s competitive positioning.
Financial StabilityAURA reported $177.3 million in cash and cash equivalents, which they expect to provide runway into the first half of 2027.